An innovative peptide system for novel drugs targeting microbial Repeats-In-Toxin adhesins
- Funded by European Commission
- Total publications:0 publications
Grant number: 899942
Grant search
Key facts
Disease
CholeraStart & end year
20202022Known Financial Commitments (USD)
$179,805Funder
European CommissionPrincipal Investigator
N/A
Research Location
NetherlandsLead Research Institution
TECHNISCHE UNIVERSITEIT EINDHOVENResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Despite progress in infection treatment in the last decades, the prevalence and mortality of infections still poses a heavy burden over humankind. The development of antimicrobial resistance and the rapid mutagenesis of bacteria that leads to inefficiency of vaccines, play an important role in maintaining infections high level of threat. Even diseases that have plagued us for centuries, such as cholera, still challenge medical professionals and cause a significant social cost. New therapeutic approaches that promise a higher success rate are a pressing need. We recently discovered a high similarity between an ice-binding protein and the RTX adhesin (FrhA) used by the bacteria of cholera to attach to and infect the human intestine. Moreover, we discovered compounds that bind to FrhA and successfully block it, suggesting these could help prevent cholera's infection. If these can also detach already adhered bacteria, cholera could be effectively removed and cured. In this ERC PoC PEPTOX project, we aim to optimise the synthesis and characterization of the newly discovered compounds and demonstrate blockage of cholera adhesion in an in vitro cellular model.